Navigation Links
New evidence for homeopathy
Date:11/3/2008

Two new studies conclude that a review which claimed that homeopathy is just a placebo, published in The Lancet, was seriously flawed.

George Lewith, Professor of Health Research at Southampton University comments: 'The review gave no indication of which trials were analysed nor of the various vital assumptions made about the data. This is not usual scientific practice. If we presume that homeopathy works for some conditions but not others, or change the definition of a 'larger trial', the conclusions change. This indicates a fundamental weakness in the conclusions: they are NOT reliable.'

The background to the ongoing debate is as follows:

In August 2005, The Lancet published an editorial entitled 'The End of Homeopathy', prompted by a review comparing clinical trials of homeopathy with trials of conventional medicine. The claim that homeopathic medicines are just placebo was based on 6 clinical trials of conventional medicine and 8 studies of homeopathy but did not reveal the identity of these trials. The review was criticised for its opacity as it gave no indication of which trials were analysed and the various assumptions made about the data.

Sufficient detail to enable a reconstruction was eventually published and two recently published scientific papers based on such a reconstruction challenge the Lancet review, showing that:

  • Analysis of all high quality trials of homeopathy yields a positive conclusion.
  • The 8 larger higher quality trials of homeopathy were all for different conditions; if homeopathy works for some of these but not others the result changes, implying that it is not placebo.
  • The comparison with conventional medicine was meaningless.
  • Doubts remain about the opaque, unpublished criteria used in the review, including the definition of 'higher quality'.

The Lancet review, led by Prof Matthias Egger of the Department of Social and Preventive Medicine at the University of Berne, started with 110 matched clinical trials of homeopathy and conventional medicine, reduced these to 'higher quality trials' and then to 8 and 6 respectively 'larger higher quality trials'. Based on these 14 studies the review concluded that there is 'weak evidence for a specific effect of homoeopathic remedies, but strong evidence for specific effects of conventional interventions'.

There are a limited number of homeopathic studies so it is quite possible to interpret these data selectively and unfavourably, which is what appears to have been done in the Lancet paper. If we assume that homeopathy does not work for just one condition (Arnica for post-exercise muscle stiffness), or alter the definition of 'larger trial', the results are positive. The comparison with conventional medicine was meaningless: the original 110 trials were matched, but matching was lost after they were reduced to 8 and 6. But the quality of homeopathic trials was better than conventional trials.

This reconstruction casts serious doubts on the review, showing that it was based on a series of hidden judgments unfavourable to homeopathy. An open assessment of the current evidence suggests that homeopathy is probably effective for a number of conditions including allergies, upper respiratory tract infections and 'flu, but more research is desperately needed.

Prof Egger has declined to comment on these findings.


'/>"/>

Contact: Peter W. Gold
peter_gold@goldorluk.com
860-674-1500
National Center for Homeopathy
Source:Eurekalert

Related medicine news :

1. First evidence that prenatal exposure to famine may lead to persistent epigenetic changes
2. AGA releases evidence-based GERD guidelines
3. New Evidence Highlights Dangers of Mercury Toxicity in Fish
4. Evidence-Based Investing: M.D. Turned Financial Advisor Diagnoses What Ails Most Investors
5. DIA Conference to Provide New Paradigms in Evidence-Based Medicine and Health Technology Assessment
6. First Comprehensive Reference on Evidence-Based Design Published
7. Louisiana May Mandate Fluoridation Despite Evidence of Harm
8. Experts from 10 countries develop first evidence-based definition of lifelong premature ejaculation
9. Researchers find first conclusive evidence of Alzheimers-like brain tangles in nonhuman primates
10. New Evidence Provides Clinicians With Better Tools to Help Smokers Quit
11. Antidepressants do work in depression while evidence for CBT is poorer say experts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... ... June 28, 2017 , ... Schneider Insurance ... assistance to clients in southern Montana, is announcing a focused charity effort to ... The outreach programs offered by Zoo Montana provide students with current knowledge on ...
(Date:6/28/2017)... ... June 28, 2017 , ... Designers ... to communities in northern Virginia and DC, is announcing a cooperative charity event ... with Alzheimer’s and other disorders that lead to memory impairment. , The Insight ...
(Date:6/27/2017)... ... 27, 2017 , ... Excel Medical, the leader in Next-Generation ... of Executive Vice President, Sales and Marketing. Finnegan is a widely known industry ... sales leadership. He has received industry recognition for innovations and new approaches to ...
(Date:6/27/2017)... PA and London UK (PRWEB) , ... June 27, 2017 , ... ... applying to a clinical study is whether they can trust the sponsor to pay ... it is vital that sponsors and CROs establish payment strategies that encourage sites to ...
(Date:6/27/2017)... ... 27, 2017 , ... Salucro, the cloud-based payment platform that ... hospitals and provider groups, has announced that it will now offer Parasail’s payment ... a San Francisco health-finance startup that has launched a series of tech-based products ...
Breaking Medicine News(10 mins):
(Date:6/3/2017)...  Eli Lilly and Company (NYSE: ... Phase 3 MONARCH 2 study showed that abemaciclib, ... combination with fulvestrant, significantly improved progression-free survival (PFS) ... with hormone-receptor-positive (HR+), human epidermal growth factor receptor ... or progressed after endocrine therapy (median PFS, 16.4 ...
(Date:5/30/2017)... May 30, 2017 DarioHealth Corp. (NASDAQ: DRIO), a leading ... today announced that it will be presenting at the 7th annual ... PT. Erez Raphael , CEO, of DarioHealth will be giving ... be held on June 6th & 7th, 2017 at the Luxe ... small / micro-cap space. About ...
(Date:5/29/2017)... 29, 2017  Cellect Biotechnology Ltd. (NASDAQ: ... enables the functional selection of stem cells, today provided ... first quarter ended March 31 st , 2017. ... in the first quarter of 2017," said Dr. Shai ... announced the treatment of the first blood cancer patient ...
Breaking Medicine Technology: